Thursday May 25th 2017

Statins may slow progression of MS

ConclusionThis was an early stage, phase II trial, which found that simvastatin reduced the rate of brain shrinkage in patients in the later stages of MS. The results are promising and warrant a larger phase III trial, examining whether the drug could slow the disease in patients at this stage of MS.  It should be noted that although simvastatin had some effect on outcomes in one disability scale and one symptom scale, the trial was primarily aimed at measuring the effect on brain shrinkage, rather than patients’ symptoms.To conclude, it is unclear what effect simvastatin, if any, would have on long-term quality of life for MS patients.A final interesting point is how simvastatin is actually reducing brain shrinkage. If we discovered the mechanisms involved, this could lead to new treat…

Excerpt from: 

Statins may slow progression of MS

Leave a Comment

More from category

MS Study Alert: Share Your Thoughts About MS Research
MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS
Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS
First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows
Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint
Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]